Evidence map›Paper›PMID 31101112›Full record

ArticleJournal of nanobiotechnology2019

Quantitative assessment of disease markers using the naked eye: point-of-care testing with gas generation-based biosensor immunochromatographic strips.

Qiangqiang Fu, Ze Wu, Jingxia Li, Zengfeng Wu, Hui Zhong, Quanli Yang, Qihui Liu, Zonghua Liu, Lianghe Sheng, Meng Xu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qiangqiang FuThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Ze WuDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510632, People's Republic of China.
Jingxia LiThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Zengfeng WuThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Hui ZhongThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Quanli YangThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Qihui LiuThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Zonghua LiuThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Lianghe ShengThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Meng XuThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China.
Tingting LiDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510632, People's Republic of China. apple-ting-007@163.com.
Zhinan YinThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China. zhinan.yin@yale.edu.
Yangzhe WuThe First Affiliated Hospital, Biomedical Translational Research Institute and School of Pharmacy and, and Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China. tyzwu@jnu.edu.cn.

Funding

Guangzhou Science and Technology Project 201604020006
6 · The paper itself

Abstract

backgroundImmunochromatographic strips (ICSs) are a practical tool commonly used in point-of-care testing (POCT) applications. However, ICSs that are currently available have low sensitivity and require expensive equipment for quantitative analysis. These limitations prohibit their extensive use in areas where medical resources are scarce.

methodsWe developed a novel POCT platform by integrating a gas generation biosensor with Au@Pt Core/Shell nanoparticle (Au@PtNPs)-based ICSs (G-ICSs). The resulting G-ICSs enabled the convenient and quantitative assessment of a target protein using the naked eye, without the need for auxiliary equipment or complicated computation. To assess this platform, C-reactive protein (CRP), a biomarker commonly used for the diagnosis of acute, infectious diseases was chosen as a proof-of-concept test.

resultsThe linear detection range (LDR) of the G-ICSs for CRP was 0.05-6.25 μg/L with a limit of detection (LOD) of 0.041 μg/L. The G-ICSs had higher sensitivity and wider LDR when compared with commonly used AuNPs and fluorescent-based ICSs. When compared with results from a chemiluminescent immunoassay, G-ICS concordance rates for CRP detection in serum samples ranged from 93.72 to 110.99%.

conclusionsThese results demonstrated that G-ICSs have wide applicability in family diagnosis and community medical institutions, especially in areas with poor medical resources.

Indexed as

Antibodies, MonoclonalBiomarkersBiosensing TechniquesChromatography, AffinityC-Reactive ProteinGasesGoldHydrogen PeroxideLimit of DetectionMetal NanoparticlesOxidation-ReductionOxygenParticle SizePoint-of-Care TestingPrinting, Three-DimensionalSurface PropertiesAntibodies, MonoclonalBiomarkersC-Reactive ProteinGasesGoldHydrogen PeroxideOxygenAu@Pt core/shell nanoparticlesC-reactive proteinGas generation-based biosensorsImmunochromatographic strips

Identifiers

PMID31101112
PMCPMC6524263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.